{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:49:54Z","timestamp":1740160194595,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s13300-020-00807-z","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T14:02:56Z","timestamp":1586440976000},"page":"1135-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type\u00a01 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme"],"prefix":"10.1007","volume":"11","author":[{"given":"Jason","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Beresford-Hulme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjeet","family":"Tank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Thor\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus Florian","family":"Scheerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"807_CR1","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbjornsdottir S, Rawshani A, et al. Type\u00a01 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https:\/\/doi.org\/10.1038\/nrdp.2017.16.","journal-title":"Nat Rev Dis Primers"},{"issue":"10138","key":"807_CR2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/s0140-6736(18)31320-5","volume":"391","author":"LA DiMzeglio","year":"2018","unstructured":"DiMzeglio LA, Evans-Molina C, Oram RA. Type\u00a01 diabetes. Lancet. 2018;391(10138):2449\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(18)31320-5.","journal-title":"Lancet"},{"key":"807_CR3","unstructured":"MedScape. Type\u00a01 diabetes mellitus 2019. http:\/\/emedicine.medscape.com\/article\/117739-overview."},{"issue":"2","key":"807_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240\u20135. https:\/\/doi.org\/10.2337\/dc09-1348.","journal-title":"Diabetes Care"},{"key":"807_CR5","unstructured":"MedScape. Only 20% with type\u00a01 diabetes are meeting HbA1c goals 2019. https:\/\/www.medscape.com\/viewarticle\/908314."},{"issue":"14","key":"807_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/nejm199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386. https:\/\/doi.org\/10.1056\/nejm199309303291401.","journal-title":"N Engl J Med"},{"issue":"10","key":"807_CR7","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2337\/diacare.24.10.1711","volume":"24","author":"The Diabetes Control and Complications Trial Research Group","year":"2001","unstructured":"The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type\u00a01 diabetes in the Diabetes Control and Complications Trial. Diabetes Care. 2001;24(10):1711\u201321.","journal-title":"Diabetes Care"},{"issue":"6","key":"807_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"9","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799\u2013812. https:\/\/doi.org\/10.1111\/j.1463-1326.2006.00686.x.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"807_CR9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1185\/03007990903073654","volume":"25","author":"M Peyrot","year":"2009","unstructured":"Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009;25(8):1985\u201393. https:\/\/doi.org\/10.1185\/03007990903073654.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"807_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic Med. 2012;29(5):682\u20139. https:\/\/doi.org\/10.1111\/j.1464-5491.2012.03605.x.","journal-title":"Diabetic Med"},{"key":"807_CR11","unstructured":"European Medicines Agency. Forxiga: EPAR - medicine overview. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forxiga-epar-medicine-overview_en.pdf. Accessed 1 Oct 2019."},{"key":"807_CR12","unstructured":"AstraZeneca K.K. and Ono Pharmaceutical Co Ltd. A selective sodium-glucose transporter (SGLT2)inhibitor Forxiga receives additional regulatory approval on indication and dosage and administration in type-1 diabetes in Japan. 2019. https:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn190327_1.pdf. Accessed 1 Oct 2019."},{"issue":"8","key":"807_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502. https:\/\/doi.org\/10.1038\/nrendo.2011.243.","journal-title":"Nat Rev Endocrinol"},{"issue":"22","key":"807_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/nejmoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/nejmoa1504720.","journal-title":"N Engl J Med"},{"issue":"7","key":"807_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/nejmoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/nejmoa1611925.","journal-title":"N Engl J Med"},{"issue":"4","key":"807_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/nejmoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/nejmoa1812389.","journal-title":"N Engl J Med"},{"issue":"11","key":"807_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/s2213-8587(17)30308-x","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type\u00a01 diabetes (DEPICT-1): 24\u00a0week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864\u201376. https:\/\/doi.org\/10.1016\/s2213-8587(17)30308-x.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"807_CR18","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"P Dandona","year":"2018","unstructured":"Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type\u00a01 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552\u20139. https:\/\/doi.org\/10.2337\/dc18-1087.","journal-title":"Diabetes Care"},{"issue":"9","key":"807_CR19","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"C Mathieu","year":"2018","unstructured":"Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type\u00a01 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938\u201346. https:\/\/doi.org\/10.2337\/dc18-0623.","journal-title":"Diabetes Care"},{"issue":"6","key":"807_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2337\/dc18-1983","volume":"42","author":"C Mathieu","year":"2019","unstructured":"Mathieu C, Dandona P, Phillip M, et al. Glucose variables in type\u00a01 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data From DEPICT-1 and -2. Diabetes Care. 2019;42(6):1081\u20137. https:\/\/doi.org\/10.2337\/dc18-1983.","journal-title":"Diabetes Care"},{"issue":"8","key":"807_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593\u2013603. https:\/\/doi.org\/10.2337\/dci19-0028.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"807_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/js.2019-SAT-LB025","volume":"3","author":"C Mathieu","year":"2019","unstructured":"Mathieu C, Dandona P, Phillip M, et al. SAT-LB025 Analysis of benefit\/risk in the subgroup of patients with BMI of >=27 kg\/m2 in the dapagliflozin DEPICT-1 and-2 trials in type\u00a01 diabetes. J Endocr Soc. 2019;3(Supplement_1):25.","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"807_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2337\/dc09-s013","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20132009. Diabetes Care. 2009;32(Suppl 1):13\u201361. https:\/\/doi.org\/10.2337\/dc09-s013.","journal-title":"Diabetes Care"},{"key":"807_CR24","unstructured":"National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes2009. https:\/\/www.eerstelijnsprotocollen.nl\/dynmedia\/8e5c5d97d8fb2bb9949e7f98b729fc7f. Accessed 1 Oct 2019."},{"key":"807_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13063-016-1207-6","volume":"17","author":"LV Viana","year":"2016","unstructured":"Viana LV, Gomes MB, Zajdenverg L, Pavin EJ, Azevedo MJ. Interventions to improve patients\u2019 compliance with therapies aimed at lowering glycated hemoglobin (HbA1c) in type\u00a01 diabetes: systematic review and meta-analyses of randomized controlled clinical trials of psychological, telecare, and educational interventions. Trials. 2016;17:94. https:\/\/doi.org\/10.1186\/s13063-016-1207-6.","journal-title":"Trials"},{"key":"807_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00728-6","author":"M Evans","year":"2019","unstructured":"Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the benefits of SGLT2 inhibitors for type\u00a01 diabetes. Diabetes Ther. 2019. https:\/\/doi.org\/10.1007\/s13300-019-00728-6.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00807-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00807-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00807-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:18:26Z","timestamp":1724411906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00807-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00807-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}